Results 1 to 10 of about 52,949 (209)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells

Applied Sciences, 2021
Gefitinib has been clinically demonstrated to be effective in the first-line setting for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
Shuang Zhao, Shangyun Lu, Lihong Fan, Hongbo Hu   +3 more
doaj   +2 more sources

miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

Scientific Reports, 2017
Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
Xiaonian Cao, Senyan Lai, Fayong Hu, Guodong Li, Guihua Wang, Xuelai Luo, Xiangning Fu, Junbo Hu   +7 more
doaj   +1 more source

Clinical Response to Gefitinib Retreatment of Lung Adenocarcinoma Patients Who Benefited from An Initial Gefitinib Therapy: A Retrospective Analysis

Chinese Journal of Lung Cancer, 2012
Background and objective Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has been widely used for the treatment of non-small cell lung cancer (NSCLC).
Junling LI, Xuezhi HAO, Yan WANG, Xiangru ZHANG, Yuankai SHI   +4 more
doaj   +1 more source

Long noncoding RNA ZMIZ1‐AS1 promotes gefitinib resistance via binding to hnRNPA1

Precision Medical Sciences, 2021
To gain an insight into the molecular mechanisms of gefitinib resistance in nonsmall cell lung cancer, we screened out the long noncoding RNA related to gefitinib resistance through microarray data in gefitinib‐sensitive and resistant cells. lncRNA ZMIZ1‐
Changwen Jing, Haixia Cao, Jianzhong Wu, Rong Ma, Junying Zhang, Siwen Liu, Zhuo Wang   +6 more
doaj   +1 more source

Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways

Saudi Pharmaceutical Journal, 2020
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use.
Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Musaad A. AlShammari, Naif O. Al-Harbi, Ali Alhoshani, Homood M. As Sobeai, Mohammed AlSwayyed, Mohammed M. AlAnazi, Nader S. AlGhamdi   +10 more
doaj   +1 more source

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells

Communications Biology
Inevitable gefitinib resistance is the biggest bottleneck in current treatment and the mechanisms are not fully understood. Here, we observe that PFTK1 (also named CDK14) is significantly enhanced in NSCLC with gefitinib resistance.
Xiaoting Jia, Jingjie Tian, Pingping Chen, Jing Dong, Lei Li, Danyang Chen, Jianlei Zhang, Dongjiang Liao, Zhimin He, Kai Luo   +9 more
doaj   +1 more source

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression

Acta Biochimica et Biophysica Sinica, 2022
Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic ...
Ren Shengnan, Zhu Ya, Wang Siying, Zhang Qinqiu, Zhang Niu, Zou Xiaoteng, Wei Chenchen, Wang Zhaoxia   +7 more
doaj   +1 more source

LncRNA AFAP1-AS1 Induces Gefitinib Resistance of Lung Adenocarcinoma Through the miR-653-5p/AGR2 Axis

Therapeutics and Clinical Risk Management, 2023
Tao Zuo,1,* Ping Jiang,2,* Jun Fu,1 Yongjian Zhang1 1Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Department of ...
Zuo T, Jiang P, Fu J, Zhang Y
doaj  

CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC

BBA Advances
While gefitinib greatly improves the prognosis of lung cancer patients with epidermal growth factor receptor (EGFR) mutation, its inevitable resistance severely diminishes therapeutic efficacy.
Li Li, Jiaxiu Xie, Jinxing Liang, Hua Su, Xiaoju Shen, Xiaoxiang Mo, Xinli Lin, Weidan Tan, Kun Wu, Fucui Zhu, Li Wang, Ying Liu   +11 more
doaj   +1 more source

LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer

Frontiers in Oncology, 2020
Lung cancer is the most common cancer globally and is associated with high morbidity and mortality. Gefitinib has been widely used for treating advanced non-small-cell lung cancer (NSCLC).
Tianwei Xu, Shuai Yan, Shuai Yan, Mengwei Wang, Lihua Jiang, Pei Ma, Binbin Lu, Qinnan Chen, Chenchen Wei, Zhaoxia Wang   +9 more
doaj   +1 more source